Oncogenic fusion proteins expressed in immature hematopoietic cells fail to recapitulate the transcriptional changes observed in human AML

Oncogenesis

Volumn 3, Issue , 2014, Pages

  Rapin, N ^a,b,c   Porse, B T ^a,b,c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c University of Copenhagen   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AML ETO FUSION PROTEIN; CD34 ANTIGEN; MLL AF9 FUSION PROTEIN; ONCOPROTEIN; UNCLASSIFIED DRUG; HYBRID PROTEIN; TRANSCRIPTOME;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; ACUTE MYELOBLASTIC LEUKEMIA; BIOINFORMATICS; CELL DIFFERENTIATION; DEREGULATION; UPREGULATION;

EID: 84902277309     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2014.22     Document Type: Article

References (26)

1. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059-2074.
2. Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012; 150: 264-278.
3. Döhner K, Dohner H. Molecular characterization of acute myeloid leukemia. Haematologica. Ferrata Storti Foundation 2008; 93: 976-982.
4. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 2007; 7: 823-833.
5. Grimwade D, Hills RK. Independent prognostic factors for AML outcome. hematology/ the education program of the American Society of Hematology. American Society of Hematology. Education Program. American Society of Hematology 2009; 2009: 385-395.
6. Metzeler KH, Hummel M, Bloomfield CD, Spiekermann K, Braess J, Sauerland M-C et al. An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood 2008; 112: 4193-4201.
7. Smith ML, Hills RK, Grimwade D. Independent prognostic variables in acute myeloid leukaemia. Blood Rev 2011; 25: 39-51.
8. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010; 116: 354-365.
9. Valk PJM, Verhaak RGW, Beijen MA, Erpelinck CAJ, Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer JM et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004; 350: 1617-1628.
10. Bullinger L, Döhner K, Bair E, Fröhling S, Schlenk RF, Tibshirani R et al. Use of geneexpression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 2004; 350: 1605-1616.
11. Haferlach T, Kohlmann A, Wieczorek L, Basso G, Kronnie GT, BénéM-C et al. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol 2010; 28: 2529-2537.
12. de Jonge HJM, Valk PJM, Veeger NJGM, Elst ter A, Boer den ML, Cloos J et al. High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia. Blood 2010; 116: 1747-1754.
13. Verhaak RGW, Wouters BJ, Erpelinck CAJ, Abbas S, Beverloo HB, Lugthart S et al. Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica. Ferrata Storti Foundation 2009; 94: 131-134.
14. Mulloy JC, Cammenga J, MacKenzie KL, Berguido FJ, Moore MAS, Nimer SD. The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells. Blood 2002; 99: 15-23.
15. Wei J, Wunderlich M, Fox C, Alvarez S, Cigudosa JC, Wilhelm JS et al. Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia. Cancer Cell 2008; 13: 483-495.
16. Rapin N, Bagger FO, Jendholm J, Mora-Jensen H, Krogh A, Kohlmann A et al. Comparing cancer vs normal gene expression profiles identifies new disease entities and common transcriptional programs in AML patients. Blood 2014; 123: 894-904.
17. Zeisig BB, Milne T, García-Cuéllar M-P, Schreiner S, Martin M-E, Fuchs U et al. Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization. Mol Cell Biol 2004; 24: 617-628.
18. Kroon E, Krosl J, Thorsteinsdottir U, Baban S, Buchberg AM, Sauvageau G. Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. EMBO J 1998; 17: 3714-3725.
19. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. Nature Publishing Group 2008; 454: 436-444.
20. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
21. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007; 7: 256-269.
22. Abdul-Nabi AM, Yassin ER, Varghese N, Deshmukh H, Yaseen NR. In vitro transformation of primary human CD34p cells by AML fusion oncogenes: early gene expression profiling reveals possible drug target in AML. PLoS ONE. Public Library of Science 2010; 5: e12464.
23. Bagger FO, Rapin N, Theilgaard-Mönch K, Kaczkowski B, Thoren LA, Jendholm J et al. HemaExplorer: a database of mRNA expression profiles in normal and malignant haematopoiesis. Nucleic Acids Res 2012; 41(Database issue): D1034-D1039.
24. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004 3 Article3.
25. Ross ME, Mahfouz R, Onciu M, Liu H-C, Zhou X, Song G et al. Gene expression profiling of pediatric acute myelogenous leukemia. Blood. American Society of Hematology 2004; 104: 3679-3687.
26. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550.